Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237

1.

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ.

J Clin Oncol. 2019 Nov 6:JCO1900172. doi: 10.1200/JCO.19.00172. [Epub ahead of print]

PMID:
31693429
2.

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.

Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Denlinger CS, Chee CE, Omori T, Leidner R, Lenz HJ, Chao Y, Rebelatto MC, Brohawn P, He P, McDevitt J, Sheth S, Englert JM, Ku GY.

Clin Cancer Res. 2019 Nov 1. pii: clincanres.2443.2019. doi: 10.1158/1078-0432.CCR-19-2443. [Epub ahead of print]

PMID:
31676670
3.

Adjuvant chemotherapy for poor pathologic response after pre-operative chemoradiation in esophageal cancer: infeasible and illogical.

Greally M, Ku GY.

J Thorac Dis. 2019 Sep;11(Suppl 15):S1855-S1860. doi: 10.21037/jtd.2019.08.116. No abstract available.

4.

Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer.

Moy RH, Dos Santos Fernandes G, Jonsson P, Chou JF, Basunia A, Ku GY, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Gabler A, Berger MF, Tang LH, Hechtman JF, Kelsen DP, Schattner M, Ilson DH, Solit DB, Taylor BS, Schultz N, Capanu M, Janjigian YY.

Oncologist. 2019 Sep 30. pii: theoncologist.2019-0492. doi: 10.1634/theoncologist.2019-0492. [Epub ahead of print]

PMID:
31570517
5.

Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.

Greally M, Chou JF, Chatila WK, Margolis M, Capanu M, Hechtman JF, Tuvy Y, Kundra R, Daian F, Ladanyi M, Kelsen DP, Ilson DH, Berger MF, Tang LH, Solit DB, Diaz LA Jr, Schultz N, Janjigian YY, Ku GY.

Clin Cancer Res. 2019 Oct 15;25(20):6160-6169. doi: 10.1158/1078-0432.CCR-18-3603. Epub 2019 Jul 23.

PMID:
31337644
6.

Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases.

Chen Y, Cheng X, Song H, Wu AJ, Ku GY, Lee P, Slingerland M, Koyanagi K, Ke S, Qiu H, Shi W, Gao Y, Chen J; written on behalf of AME Radiation Oncology Collaborative Group.

J Thorac Dis. 2019 Apr;11(4):1536-1545. doi: 10.21037/jtd.2019.03.10.

7.

Maximizing response: a case report of salvage chemotherapy after immune checkpoint inhibition in a patient with previous chemo-refractory metastatic esophageal carcinoma.

Greally M, Agarwal R, El Dika I, Shamseddine A, El-Olayan A, Haibe Y, Paroder V, Shia J, Abou-Alfa GK, Ku GY.

J Gastrointest Oncol. 2019 Apr;10(2):367-372. doi: 10.21037/jgo.2018.10.07.

8.

Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer.

Won E, Basunia A, Chatila WK, Hechtman JF, Chou JF, Ku GY, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Tuvy Y, Berger MF, Tang L, Kelsen DP, Schattner M, Ilson DH, Capanu M, Solit DB, Schultz N, Janjigian YY.

Clin Cancer Res. 2019 Jul 1;25(13):3811-3817. doi: 10.1158/1078-0432.CCR-18-3789. Epub 2019 Apr 5.

PMID:
30952642
9.

Wirelessly Controlled Implantable System for On-demand and Pulsatile Insulin Administration.

Lee SH, Ahn JW, Cho YC, Kim SN, Lee C, Ku GW, Bin Choy Y, Kim HC.

Sci Rep. 2019 Mar 21;9(1):5009. doi: 10.1038/s41598-019-41430-8.

10.

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway.

Ku GY.

Oncology (Williston Park). 2019 Mar 13;33(3):110-2. No abstract available.

11.

The Current Status of Immunotherapies in Esophagogastric Cancer.

Ku GY.

Hematol Oncol Clin North Am. 2019 Apr;33(2):323-338. doi: 10.1016/j.hoc.2018.12.007. Review.

PMID:
30833003
12.

Immune checkpoint inhibitors in esophagogastric adenocarcinoma: do the results justify the hype?

Greally M, Ku GY.

J Thorac Dis. 2018 Dec;10(12):6407-6411. doi: 10.21037/jtd.2018.12.01. No abstract available.

13.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT.

Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.

PMID:
30643254
14.

Comment on "Microsatellite Instability as a Predictive Biomarker for Adjuvant Chemotherapy in Gastric Cancer": Are we There Yet?

Mondaca S, Yoon SS, Strong VE, Ku GY, Ilson DH, Greally M, Janjigian YY.

Ann Surg. 2019 Aug;270(2):e39-e40. doi: 10.1097/SLA.0000000000003100. No abstract available.

PMID:
30480560
15.

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY.

Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21.

PMID:
30463996
16.

Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders.

Greally M, Chou JF, Molena D, Rusch VW, Bains MS, Park BJ, Wu AJ, Goodman KA, Kelsen DP, Janjigian YY, Ilson DH, Ku GY.

J Thorac Oncol. 2019 Mar;14(3):540-546. doi: 10.1016/j.jtho.2018.10.152. Epub 2018 Nov 1.

PMID:
30391577
17.

Outcomes of Radiation-Associated Esophageal Squamous Cell Carcinoma: The MSKCC Experience.

Nobel TB, Barbetta A, Hsu M, Tan KS, Pinchinat T, Schlottmann F, Bains MS, Ku GY, Wu AJ, Patti MG, Jones DR, Molena D.

J Gastrointest Surg. 2019 Jan;23(1):11-22. doi: 10.1007/s11605-018-3958-8. Epub 2018 Sep 13.

PMID:
30215197
18.

Thoracic Scoliosis in Patients with Primary Spontaneous Pneumothorax.

Lee Y, Kim YJ, Ryu HY, Ku GW, Sung TY, Yoon YS, Kim TK.

Korean J Thorac Cardiovasc Surg. 2018 Aug;51(4):254-259. doi: 10.5090/kjtcs.2018.51.4.254. Epub 2018 Aug 5.

19.

Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.

Mondaca S, Margolis M, Sanchez-Vega F, Jonsson P, Riches JC, Ku GY, Hechtman JF, Tuvy Y, Berger MF, Shah MA, Kelsen DP, Ilson DH, Yu K, Goldberg Z, Epstein AS, Desai A, Chung V, Chou JF, Capanu M, Solit DB, Schultz N, Janjigian YY.

Gastric Cancer. 2019 Mar;22(2):355-362. doi: 10.1007/s10120-018-0861-7. Epub 2018 Aug 7.

PMID:
30088161
20.

A Genetic Interaction Map of Insulin Production Identifies Mfi as an Inhibitor of Mitochondrial Fission.

Lee J, Pappalardo Z, Chopra DG, Hennings TG, Vaughn I, Lan C, Choe JJ, Ang K, Chen S, Arkin M, McManus MT, German MS, Ku GM.

Endocrinology. 2018 Sep 1;159(9):3321-3330. doi: 10.1210/en.2018-00426.

21.

In Vivo Deletion of β-Cell Drp1 Impairs Insulin Secretion Without Affecting Islet Oxygen Consumption.

Hennings TG, Chopra DG, DeLeon ER, VanDeusen HR, Sesaki H, Merrins MJ, Ku GM.

Endocrinology. 2018 Sep 1;159(9):3245-3256. doi: 10.1210/en.2018-00445.

22.

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.

Glassman DC, Palmaira RL, Covington CM, Desai AM, Ku GY, Li J, Harding JJ, Varghese AM, O'Reilly EM, Yu KH.

BMC Cancer. 2018 Jun 27;18(1):693. doi: 10.1186/s12885-018-4605-1.

23.

Spatial and Temporal Confined Photothermolysis of Cancer Cells Mediated by Hollow Gold Nanospheres Targeted to Epidermal Growth Factor Receptors.

Ku G, Huang Q, Wen X, Ye J, Piwnica-Worms D, Li C.

ACS Omega. 2018 May 31;3(5):5888-5895. doi: 10.1021/acsomega.8b00712.

24.

Unusual Pseudoaneurysm of the Dorsalis Pedis Artery after an Iatrogenic Injury.

Lee Y, Ryu HY, Kim YJ, Ku GW.

Korean J Thorac Cardiovasc Surg. 2018 Jun;51(3):213-215. doi: 10.5090/kjtcs.2018.51.3.213. Epub 2018 Jun 5.

25.

Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.

Barbetta A, Hsu M, Tan KS, Stefanova D, Herman K, Adusumilli PS, Bains MS, Bott MJ, Isbell JM, Janjigian YY, Ku GY, Park BJ, Wu AJ, Jones DR, Molena D.

J Thorac Cardiovasc Surg. 2018 Jun;155(6):2710-2721.e3. doi: 10.1016/j.jtcvs.2018.01.086. Epub 2018 Feb 15.

26.

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.

Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH.

JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013. Epub 2018 May 10.

27.

The Transcriptionally Permissive Chromatin State of Embryonic Stem Cells Is Acutely Tuned to Translational Output.

Bulut-Karslioglu A, Macrae TA, Oses-Prieto JA, Covarrubias S, Percharde M, Ku G, Diaz A, McManus MT, Burlingame AL, Ramalho-Santos M.

Cell Stem Cell. 2018 Mar 1;22(3):369-383.e8. doi: 10.1016/j.stem.2018.02.004.

28.

The Cultural Boundaries of Perspective-Taking: When and Why Perspective-Taking Reduces Stereotyping.

Wang CS, Lee M, Ku G, Leung AK.

Pers Soc Psychol Bull. 2018 Jun;44(6):928-943. doi: 10.1177/0146167218757453. Epub 2018 Feb 28.

PMID:
29486634
29.

Systemic therapy for esophagogastric cancer: immune checkpoint inhibition.

Lyons TG, Ku GY.

Chin Clin Oncol. 2017 Oct;6(5):53. doi: 10.21037/cco.2017.09.03.

30.

Systemic therapy for esophageal cancer: chemotherapy.

Ku GY.

Chin Clin Oncol. 2017 Oct;6(5):49. doi: 10.21037/cco.2017.07.06. Review.

31.

Systemic therapy for esophagogastric cancer: targeted therapies.

Lyons TG, Ku GY.

Chin Clin Oncol. 2017 Oct;6(5):48. doi: 10.21037/cco.2017.07.02. Review.

32.

Preface on Esophagus Cancer.

Ku GY, Ilson DH.

Chin Clin Oncol. 2017 Oct;6(5):44. doi: 10.21037/cco.2017.10.04. No abstract available.

33.

Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.

Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, Riches JC, Tuvy Y, Kundra R, Bouvier N, Vakiani E, Gao J, Heins ZJ, Gross BE, Kelsen DP, Zhang L, Strong VE, Schattner M, Gerdes H, Coit DG, Bains M, Stadler ZK, Rusch VW, Jones DR, Molena D, Shia J, Robson ME, Capanu M, Middha S, Zehir A, Hyman DM, Scaltriti M, Ladanyi M, Rosen N, Ilson DH, Berger MF, Tang L, Taylor BS, Solit DB, Schultz N.

Cancer Discov. 2018 Jan;8(1):49-58. doi: 10.1158/2159-8290.CD-17-0787. Epub 2017 Nov 9.

34.

The effect of text message support on diabetes self-management in developing countries - A randomised trial.

Van Olmen J, Kegels G, Korachais C, de Man J, Van Acker K, Kalobu JC, van Pelt M, Ku GM, Hen H, Kanda D, Malombo B, Darras C, Schellevis F.

J Clin Transl Endocrinol. 2017 Jan 3;7:33-41. doi: 10.1016/j.jcte.2016.12.005. eCollection 2017 Mar.

35.

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis.

Ridouane Y, Lopes G, Ku G, Masud H, Haaland B.

Oncotarget. 2017 Aug 11;8(39):66458-66466. doi: 10.18632/oncotarget.20185. eCollection 2017 Sep 12.

36.

Laser streaming: Turning a laser beam into a flow of liquid.

Wang Y, Zhang Q, Zhu Z, Lin F, Deng J, Ku G, Dong S, Song S, Alam MK, Liu D, Wang Z, Bao J.

Sci Adv. 2017 Sep 27;3(9):e1700555. doi: 10.1126/sciadv.1700555. eCollection 2017 Sep.

37.

Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.

Vellayappan BA, Soon YY, Ku GY, Leong CN, Lu JJ, Tey JC.

Cochrane Database Syst Rev. 2017 Aug 22;8:CD010511. doi: 10.1002/14651858.CD010511.pub2. Review.

38.

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma.

Ku G, Ilson D.

Lancet Oncol. 2017 May;18(5):e243. doi: 10.1016/S1470-2045(17)30280-2. No abstract available.

PMID:
28495288
39.

The Current Status of Immunotherapies in Esophagogastric Cancer.

Ku GY.

Surg Oncol Clin N Am. 2017 Apr;26(2):277-292. doi: 10.1016/j.soc.2016.10.012. Review.

PMID:
28279469
40.

Controversies and Consensus in Preoperative Therapy of Esophageal and Gastroesophageal Junction Cancers.

Ku GY.

Surg Oncol Clin N Am. 2017 Apr;26(2):241-256. doi: 10.1016/j.soc.2016.10.009. Epub 2017 Feb 9. Review.

PMID:
28279467
41.

A Whole-Genome RNA Interference Screen Reveals a Role for Spry2 in Insulin Transcription and the Unfolded Protein Response.

Pappalardo Z, Gambhir Chopra D, Hennings TG, Richards H, Choe J, Yang K, Baeyens L, Ang K, Chen S, Arkin M, German MS, McManus MT, Ku GM.

Diabetes. 2017 Jun;66(6):1703-1712. doi: 10.2337/db16-0962. Epub 2017 Feb 28.

42.

Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma.

Ku GY, Bains MS, Park DJ, Janjigian YY, Rusch VW, Rizk NP, Yoon SS, Millang B, Capanu M, Goodman KA, Ilson DH.

J Gastrointest Oncol. 2016 Dec;7(6):828-837. doi: 10.21037/jgo.2016.08.09.

43.

64 CuS-labeled nanoparticles: a new sentinel-lymph-node-mapping agent for PET-CT and photoacoustic tomography.

Liu Q, Zhou M, Li P, Ku G, Huang G, Li C, Song S.

Contrast Media Mol Imaging. 2016 Nov;11(6):475-481. doi: 10.1002/cmmi.1709. Epub 2016 Aug 15.

PMID:
27523742
44.

NCCN Guidelines Insights: Survivorship, Version 1.2016.

Denlinger CS, Ligibel JA, Are M, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Jones LW, King A, Ku GH, Kvale E, Langbaum TS, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Sanft T, Silverman P, Smith S, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA.

J Natl Compr Canc Netw. 2016 Jun;14(6):715-24.

45.

Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.

Ku GY, Kriplani A, Janjigian YY, Kelsen DP, Rusch VW, Bains M, Chou J, Capanu M, Wu AJ, Goodman KA, Ilson DH.

Cancer. 2016 Jul 1;122(13):2083-90. doi: 10.1002/cncr.30028. Epub 2016 May 6.

46.

Traumatic intrapericardial diaphragmatic hernia: findings on a computed tomography scan.

Choi MS, Ku GW, Park SS, Choi SY, Choi JH.

ANZ J Surg. 2018 May;88(5):E473-E474. doi: 10.1111/ans.13430. Epub 2015 Dec 23. No abstract available.

PMID:
26695101
47.

Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma.

Chhabra A, Ong LT, Kuk D, Ku G, Ilson D, Janjigian YY, Wu A, Schöder H, Goodman KA.

Br J Cancer. 2015 Dec 22;113(12):1658-65. doi: 10.1038/bjc.2015.416. Epub 2015 Dec 10.

48.

Process evaluation of a mobile health intervention for people with diabetes in low income countries - the implementation of the TEXT4DSM study.

Van Olmen J, Van Pelt M, Malombo B, Ku GM, Kanda D, Heang H, Darras C, Kegels G, Schellevis F.

J Telemed Telecare. 2017 Jan;23(1):96-105. doi: 10.1177/1357633X15617885. Epub 2016 Jul 8.

PMID:
26656894
49.

Spanning the canyon between stem cell transplantation and palliative care.

Roeland E, Ku G.

Hematology Am Soc Hematol Educ Program. 2015;2015:484-9. doi: 10.1182/asheducation-2015.1.484.

PMID:
26637762
50.

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma.

Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger NM, Hari PN, Ku GH, Ayala E, Chen AI, Chen YB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Martino R, Mussetti A, Savani BN, Schouten HC, Usmani SZ, Wiernik PH, Wirk B, Smith SM, Sureda A, Hamadani M.

Bone Marrow Transplant. 2016 Jan;51(1):58-66. doi: 10.1038/bmt.2015.223. Epub 2015 Oct 5.

Supplemental Content

Support Center